Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Mexico / NCT07100080
Recruiting Phase 2/3

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT07100080 · tracked via the Priya Life Science Mexico tracker
Sponsor
Bristol-Myers Squibb
Phase
Phase 2/3
Started
2025-11-05
Last updated
2026-10-09

Condition(s) studied

Non-Small Cell Lung Cancer

Investigational drug(s) / intervention(s)

Iza-bren →Carboplatin →Cisplatin →Pemetrexed →

Iza-bren: Specified dose on specified days

Carboplatin: Specified dose on specified days

Cisplatin: Specified dose on specified days

Pemetrexed: Specified dose on specified days

Study summary

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Non-squamous NSCLC, not amenable to treatment in curative intent. * Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation). * Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib, lazertinib,...) EGFR-TKI-based mono- or combination therapy regimen as the most recent line of therapy in an adjuvant, locally advanced, or metastatic treatment setting. * Eligible to receive a platinum-based doublet chemotherapy regimen (either cisplatin or carboplatin in combination with pemetrexed). Exclusion criteria: * Inadequate organ function and/or bone marrow reserve. * Leptomeningeal metastases or spinal cord compression. * Poorly controlled systemic medical conditions. * Other protocol-defined inclusion/exclusion criteria apply.

Primary outcome measure(s)

  • Recommended Phase 3 Dose (RP3D) of BMS-986507 — Approximately 3 months after the first dose
    Phase 2
  • Progression-Free Survival (PFS) Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR) — Up to 3 years
    Phase 3

Trial sites (187)

FacilityCityRegionStatus
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care building Irvine California Recruiting
University of California, Irvine (UCI) Health - UC Irvine Medical Center Orange California Recruiting
Shaw Cancer Center Edwards Colorado Recruiting
Local Institution - 0085 Gainesville Florida Withdrawn
Local Institution - 0142 Pembroke Pines Florida Not Yet Recruiting
Piedmont Healthcare Atlanta Georgia Recruiting
John B Amos Cancer Center Columbus Georgia Recruiting
Rush University Medical Center Chicago Illinois Recruiting
Dana-Farber Cancer Institute Boston Massachusetts Recruiting
Washington University School of Medicine St Louis Missouri Recruiting
Renown Regional Medical Center Reno Nevada Recruiting
Perlmutter Cancer Center at NYU Langone Hospital - Long Island Mineola New York Recruiting
NYU Langone Health New York New York Recruiting
Weill Cornell Medical College New York New York Recruiting
Rochester General Hospital Infectious Disease Rochester New York Recruiting
University Hospitals Cleveland Medical Center Cleveland Ohio Recruiting
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C Columbus Ohio Recruiting
Providence Cancer Institute Franz Clinic Portland Oregon Recruiting
Providence St. Vincent Medical Center Portland Oregon Recruiting
Oregon Health and Science University Portland Oregon Recruiting
Hospital of the University of Pennsylvania Philadelphia Pennsylvania Recruiting
West Penn Allegheny Health Pittsburgh Pennsylvania Recruiting
Local Institution - 0268 Chattanooga Tennessee Withdrawn
Tennessee Oncology Nashville Tennessee Recruiting
Local Institution - 0025 Houston Texas Not Yet Recruiting
Local Institution - 0173 San Antonio Texas Not Yet Recruiting
University of Virginia Health System Charlottesville Virginia Recruiting
Virginia Commonwealth University (Vcu) Richmond Virginia Recruiting
Instituto Alexander Fleming Ciudad Autónoma de Buenos Aires Buenos Aires Recruiting
Hospital Italiano de Buenos Aires ABB Buenos Aires F.D. Recruiting
Hospital Privado Universitario de Córdoba Córdoba Argentina Recruiting
Local Institution - 0280 Wilrijk Antwerpen Not Yet Recruiting
Local Institution - 0161 Auderghem Bruxelles-Capitale, Région de Not Yet Recruiting
Local Institution - 0022 Yvoir Namur Not Yet Recruiting
Local Institution - 0023 Ghent Oost-Vlaanderen Not Yet Recruiting
Local Institution - 0024 Sint-Niklaas Oost-Vlaanderen Not Yet Recruiting
Arthur J. E. Child Comprehensive Cancer Centre Calgary Alberta Recruiting
Princess Margaret Cancer Centre Toronto Ontario Recruiting
Local Institution - 0184 Chicoutimi Quebec Not Yet Recruiting
Local Institution - 0185 Montreal Quebec Withdrawn

+ 147 more sites — see the full list on the official registry below.

More Bristol-Myers Squibb trials in Mexico

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation Active, not recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) Recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis Active, not recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) Recruiting

Other trials for the same condition

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC Active, not recruiting
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] Recruiting
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer Active, not recruiting
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07100080 on ClinicalTrials.gov ↗ ← All trials in Mexico